Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics (Nasdaq: KPTI) has announced the granting of 28,000 restricted stock units (RSUs) to three newly-hired employees as of January 31, 2025. These RSU awards were granted under the Company's 2022 Inducement Stock Incentive Plan, in compliance with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest over three years, with 33 1/3% vesting on each anniversary of the grant date, contingent upon continued employment. In case of a change in control event, the RSUs will fully vest if the employee's employment is terminated for good reason or without cause within one year of such event.
Karyopharm Therapeutics (Nasdaq: KPTI) ha annunciato l'assegnazione di 28.000 unità azionarie limitate (RSUs) a tre nuovi dipendenti a partire dal 31 gennaio 2025. Questi premi RSU sono stati concessi nell'ambito del Piano di Incentivi Azionari per Induzione 2022 dell'azienda, in conformità alla Regola di Quotazione 5635(c)(4) di Nasdaq.
Le RSUs matureranno in tre anni, con il 33 1/3% che matura ad ogni anniversario della data di concessione, subordinato al mantenimento dell'impiego. In caso di un evento di cambiamento di controllo, le RSUs matureranno completamente se l'impiego del dipendente viene terminato per giusta causa o senza motivo entro un anno da tale evento.
Karyopharm Therapeutics (Nasdaq: KPTI) ha anunciado la concesión de 28,000 unidades de acciones restringidas (RSUs) a tres empleados recién contratados a partir del 31 de enero de 2025. Estos premios de RSU se otorgaron bajo el Plan de Incentivos de Acciones por Inducción 2022 de la compañía, cumpliendo con la Regla de Cotización 5635(c)(4) de Nasdaq.
Las RSUs se consolidarán en tres años, con un 33 1/3% consolidándose en cada aniversario de la fecha de concesión, condicionadas a la continuidad del empleo. En caso de un evento de cambio de control, las RSUs se consolidarán completamente si el empleo del empleado es terminado por causa justificada o sin causa dentro de un año tras dicho evento.
Karyopharm Therapeutics (Nasdaq: KPTI)는 2025년 1월 31일자로 새로 채용된 세 명의 직원에게 28,000 제한 주식 단위(RSU)를 부여했다고 발표했습니다. 이 RSU 지급은 회사의 2022 유인 스톡 인센티브 계획에 따라 Nasdaq 상장 규칙 5635(c)(4)를 준수하여 승인되었습니다.
RSU는 3년에 걸쳐 행사됩니다, 부여일의 기념일마다 33 1/3%씩 행사되며, 계속 근무하는 것을 조건으로 합니다. 통제권 변경 사건이 발생할 경우, 해당 사건 발생 후 1년 이내에 직원의 고용이 정당한 사유로 종료되거나 무단으로 종료되는 경우 RSU는 전부 행사됩니다.
Karyopharm Therapeutics (Nasdaq: KPTI) a annoncé l'octroi de 28 000 unités d'actions restreintes (RSUs) à trois nouveaux employés à compter du 31 janvier 2025. Ces attributions de RSU ont été faites dans le cadre du Plan d'Incitation au Capital 2022 de la société, en conformité avec la Règle d'Enregistrement 5635(c)(4) de Nasdaq.
Les RSUs acquerront des droits sur trois ans, avec 33 1/3 % acquérant des droits à chaque anniversaire de la date d'attribution, sous condition de maintenir l'emploi. En cas de changement de contrôle, les RSUs seront entièrement acquises si l'emploi de l'employé est résilié pour une raison valable ou sans motif dans l'année suivant cet événement.
Karyopharm Therapeutics (Nasdaq: KPTI) hat die Gewährung von 28.000 eingeschränkten Aktieneinheiten (RSUs) an drei neu eingestellte Mitarbeiter ab dem 31. Januar 2025 angekündigt. Diese RSU-Auszeichnungen wurden im Rahmen des Aktienoptionsplans 2022 des Unternehmens gewährt, im Einklang mit der Nasdaq-Listing-Regel 5635(c)(4).
Die RSUs werden über einen Zeitraum von drei Jahren erworben, wobei 33 1/3 % an jedem Jahrestag des Gewährungsdatums fällig werden, abhängig von der Fortsetzung der Beschäftigung. Im Falle eines Kontrollwechselereignisses erwerben die RSUs vollständig, wenn die Anstellung des Mitarbeiters aus einem triftigen Grund oder ohne Grund innerhalb eines Jahres nach solchem Ereignis beendet wird.
- Stock-based compensation aligns employee interests with shareholders
- Structured vesting schedule helps retain talent over three years
- 28,000 new RSUs will cause minor shareholder dilution
- Additional stock-based compensation expenses will impact financial statements
Each RSU award will vest over three years, with 33 1/
In addition, each RSU award will be immediately exercisable in full if, on or prior to the first anniversary of the consummation of a "change in control event," the employee's employment is terminated for "good reason" by the employee or terminated without "cause" by Karyopharm (as such terms are defined in the 2022 Inducement Stock Incentive Plan, as amended).
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and firstinclass, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302363681.html
SOURCE Karyopharm Therapeutics Inc.
FAQ
How many RSUs did Karyopharm (KPTI) grant to new employees in January 2025?
What is the vesting schedule for KPTI's January 2025 RSU grants?
What happens to KPTI's RSU grants in case of a change in control event?
Under which plan did Karyopharm (KPTI) issue the January 2025 RSU grants?
